Skip to main content

Table 5 Correlation between objective (pH) and patient reported subjective outcomes in study patients PPI group on PPIs (6 months following high-dose PPI therapy)

From: Efficacy of transoral fundoplication for treatment of chronic gastroesophageal reflux disease incompletely controlled with high-dose proton-pump inhibitors therapy: a randomized, multicenter, open label, crossover study

Parameters Regurgitation RSI GERD-HRQL DMS % total time RE
Regurgitation 1.00      
RSI 0.70 (<0.001) 1.00     
GERD-HRQL 0.59 (0.005) 0.71 (<0.001) 1.00    
DMS −0.20 (0.399) 0.05 (0.838) 0.38 (0.107) 1.00   
% total time −0.12 (0.619) 0.12 (0.598) 0.41 (0.063) 0.94 (<0.001) 1.00  
RE 0.10 (0.667) 0.31 (0.167) 0.46 (0.035) 0.77 (<0.001) 0.84 (<0.001) 1.00
Crossover patients off PPIs (6 months following transoral fundoplication)
Parameters Regurgitation RSI GERD-HRQL DMS % total time RE
Regurgitation 1.00      
RSI 0.71 (<0.001) 1.00     
GERD-HRQL 0.81 (<0.001) 0.62 (0.003) 1.00    
DMS 0.18 (0.428) 0.14 (0.556) 0.04 (0.866) 1.00   
% total time 0.11 (0.637) 0.09 (0.705) 0.08 (0.746) 0.89 (<0.001) 1.00  
RE 0.17 (0.461) 0.14 (0.546) 0.14 (0.543) 0.65 (0.001) 0.80 (<0.001) 1.00
TF group off PPIs (12 months following transoral fundoplication)
Parameters Regurgitation RSI GERD-HRQL DMS % total time RE
Regurgitation 1.00      
RSI 0.66 (<0.001) 1.00     
GERD-HRQL 0.42 (0.010) 0.73 (<0.001) 1.00    
DMS 0.02 (0.885) 0.10 (0.550) 0.35 (0.036) 1.00   
% total time 0.06 (0.724) 0.10 (0.552) 0.39 (0.018) 0.98 (<0.001) 1.00  
RE 0.21 (0.216) 0.13 (0.424) 0.41 (0.013) 0.83 (<0.001) 0.84 (<0.001) 1.00
  1. Values are Spearman’s Rho (p values).
  2. DMS, DeMeester score; GERD-HRQL, gastroesophageal reflux disease health-related quality of life; PPI, proton pump inhibitor; RE, reflux episodes; RSI, Reflux Symptom Index.
  3. Regurgitation was assessed with Reflux Disease questionnaire. RSI was used to assess atypical symptoms. GERD-HRQL was used to assess typical symptoms.